*CRISPR THERAPEUTICS HIGHLIGHTS STRATEGIC PRIORITIES AND ANTICIPATED 2025 MILESTONES
*TO ENGAGE REGULATORS ON CTX112 PATH FORWARD, UPDATE MID-2025
*DOSE ESCALATION FOR CTX310 AND CTX320 ONGOING, UPDATES EXPECTED H1 2025
*ONGOING LAUNCH OF CASGEVY DRIVEN BY STRONG PATIENT DEMAND
((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 13-JAN-202512:00:00.877 GMT